trihexyphenidyl has been researched along with Parkinson Disease, Secondary in 38 studies
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind study was carried out on the therapeutic effects of dexetimide and artane in the control of neuroleptic-induced extrapyramidal side-effects in 261 cases of schizophrenia." | 5.07 | [A double-blind study on the effect of dexetimide in the control of neuroleptic-induced extrapyramidal side-effects]. ( Chen, Y, 1991) |
| "Amantadine is a putative dopaminergic compound known to be therapeutically effective in idiopathic and postencephalitic Parkinson's disease." | 2.64 | Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. ( Fann, WE; Lake, CR, 1976) |
| "Trihexyphenidyl was then studied in combination with the selective dopamine receptor D1 agonist SKF-82958 [(+/-)-6-chloro-7-8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro- 1H-benzazepine hydrobromide] and the selective D2 agonist N-0923 [(-)2-(N-propyl-N-2-thienylethyl)amino-5-hydroxytetralin HCl] on rotational behavior in five 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned hemiparkinsonian monkeys." | 1.30 | Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys. ( Domino, EF; Ni, L, 1998) |
| " After chronic haloperidol dosing (vehicle, 0." | 1.30 | Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism. ( Fowler, SC; Wang, G, 1998) |
| " Both studies yielded significant correlations between memory impairment and dosage levels of benzhexol." | 1.27 | The adverse effect of benzhexol on memory in Parkinson's disease. ( Berrios, GE; Miller, E; Politynska, B, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (73.68) | 18.7374 |
| 1990's | 7 (18.42) | 18.2507 |
| 2000's | 3 (7.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bata-García, JL | 1 |
| Villanueva-Toledo, J | 1 |
| Gutiérrez-Ospina, G | 1 |
| Alvarez-Cervera, FJ | 1 |
| Heredia-López, FJ | 1 |
| Góngora-Alfaro, JL | 1 |
| Panagariya, A | 1 |
| Sharma, B | 1 |
| Dev, A | 1 |
| Lee, WK | 1 |
| Yu, ZH | 1 |
| Lee, CC | 1 |
| McInnis, M | 1 |
| Petursson, H | 1 |
| Magnus, RV | 1 |
| Ondo, WG | 1 |
| Hurwitz, BJ | 1 |
| Picard, F | 1 |
| de Saint-Martin, A | 1 |
| Salmon, E | 1 |
| Hirsch, E | 1 |
| Marescaux, C | 1 |
| Domino, EF | 2 |
| Ni, L | 2 |
| Fowler, SC | 1 |
| Wang, G | 1 |
| Kolakowska, T | 1 |
| Wiles, DH | 1 |
| Gelder, MG | 1 |
| McNeilly, AS | 1 |
| Matthews, RT | 1 |
| Chiou, CY | 1 |
| Davis, KL | 1 |
| Yesavage, JA | 1 |
| Berger, PA | 1 |
| Agnoli, A | 1 |
| Ruggieri, S | 1 |
| Denaro, A | 1 |
| Lelli, A | 1 |
| Fann, WE | 1 |
| Lake, CR | 1 |
| Crow, TJ | 1 |
| Johnstone, EC | 1 |
| McClelleand, HA | 1 |
| Evtushenko, SK | 1 |
| Chen, Y | 1 |
| Kryzhanovskiĭ, GN | 3 |
| Shandra, AA | 2 |
| Godlevskiĭ, LS | 2 |
| Mikhaleva, II | 1 |
| Wirshing, WC | 1 |
| Freidenberg, DL | 1 |
| Cummings, JL | 1 |
| Bartzokis, G | 1 |
| Atadzhanov, MA | 1 |
| Voronina, TA | 1 |
| Nerobkova, LN | 1 |
| Vågen, R | 1 |
| Götestam, KG | 1 |
| Fayen, M | 1 |
| Goldman, MB | 1 |
| Moulthrop, MA | 1 |
| Luchins, DJ | 1 |
| Hardie, RJ | 1 |
| Lees, AJ | 1 |
| Saitoh, T | 1 |
| Makul'kin, RF | 1 |
| Rozhkov, VS | 1 |
| Miller, E | 1 |
| Berrios, GE | 1 |
| Politynska, B | 1 |
| Carotti, A | 1 |
| Tomassetti, G | 1 |
| Lucciarini, L | 1 |
| Barone, G | 1 |
| Mugnai, A | 1 |
| Klawans, HL | 1 |
| Bordeleau, JM | 1 |
| Tétreault, L | 1 |
| Dreyfuss, J | 1 |
| Beer, B | 1 |
| Devine, DD | 1 |
| Roberts, BF | 1 |
| Schreiber, EC | 1 |
| Freeman, H | 1 |
| Mehta, IS | 1 |
| Pecknold, JC | 1 |
| Ananth, JV | 1 |
| Ban, TA | 1 |
| Lehmann, HE | 1 |
| Ridges, AP | 1 |
| Harper, P | 1 |
| Gjerris, F | 1 |
| Maller, O | 1 |
| Heller, S | 1 |
| Dandiya, PC | 1 |
| Bhargava, LP | 1 |
| Grabowski, K | 1 |
1 review available for trihexyphenidyl and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The pharmacology of parkinsonism (a review).
Topics: Acetylcholine; Animals; Atropa belladonna; Atropine; Central Nervous System; Chlorpromazine; Dextroa | 1968 |
9 trials available for trihexyphenidyl and Parkinson Disease, Secondary
| Article | Year |
|---|---|
A comparison of biperiden hydrochloride (Akineton) and benzhexol (Artane) in the treatment of drug-induced Parkinsonism.
Topics: Adolescent; Adult; Biperiden; Female; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Piper | 1980 |
Clinical significance of plasma chlorpromazine levels. II. Plasma levels of the drug, some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Drug Tolerance; Female; Humans; Male; Middle Aged; Park | 1976 |
Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism.
Topics: Amantadine; Clinical Trials as Topic; Humans; Parkinson Disease, Secondary; Tranquilizing Agents; Tr | 1976 |
[A double-blind study on the effect of dexetimide in the control of neuroleptic-induced extrapyramidal side-effects].
Topics: Adolescent; Adult; Antipsychotic Agents; Dexetimide; Double-Blind Method; Female; Humans; Male; Midd | 1991 |
Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Human | 1989 |
An experimental evaluation of the euphoric properties of antiparkinson drugs on psychotic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Euphoria; Female; Humans; Male; | 1986 |
Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms.
Topics: Adult; Amantadine; Antipsychotic Agents; Cerebral Ventricles; Clinical Trials as Topic; Dilatation, | 1988 |
A double-blind comparison of the efficacy of EX 10-029 and trihexyphenidyl hydrochloride in relieving drug-induced Parkinsonian symptoms.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Female; Humans; Male; Methods; Middle Aged; Parkinso | 1972 |
Neutralization of extrapyramidal side-effects with Methixene.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Extrapyramidal Tracts; Female; Humans; Male; Middle Age | 1971 |
28 other studies available for trihexyphenidyl and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Sustained improvement of motor function in hemiparkinsonian rats chronically treated with low doses of caffeine or trihexyphenidyl.
Topics: Animals; Antiparkinson Agents; Brain; Caffeine; Central Nervous System Stimulants; Dose-Response Rel | 2007 |
Pallido-pyramidal syndrome: a rare entity.
Topics: Adult; Antiparkinson Agents; Globus Pallidus; Humans; Male; Parkinson Disease, Secondary; Pyramidal | 2007 |
Delayed neurological sequelae after carbon monoxide poisoning.
Topics: Adult; Antiparkinson Agents; Brain; Brain Infarction; Carbon Monoxide Poisoning; Cognition Disorders | 2008 |
Trihexyphenidyl dependence.
Topics: Adult; Anxiety; Female; Humans; Male; Parkinson Disease, Secondary; Substance Withdrawal Syndrome; S | 1984 |
Tardive dyskinesia and pseudo-parkinsonism. In a nursing home patient who itched.
Topics: Aged; Clonazepam; Dyskinesia, Drug-Induced; Extrapyramidal Tracts; Female; Humans; Parkinson Disease | 1993 |
Postencephalitic stereotyped involuntary movements responsive to L-Dopa.
Topics: Adult; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Encephalitis; Humans; Levodopa; | 1996 |
Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dopamine Agonists; Dose-Response Relationship, Drug; Dr | 1998 |
Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, | 1998 |
Trihexyphenidyl potentiation of L-DOPA: reduced effectiveness three years later in MPTP-induced chronic hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Chronic Disease; Dopamine Agents; Dose-Response Relationship, Drug; D | 1998 |
Effects of diethylcholine in two animal models of Parkinsonism tremors.
Topics: Animals; Brain Chemistry; Carbachol; Choline; Disease Models, Animal; Male; Mice; Parkinson Disease, | 1979 |
Single case study. Possible organophosphate-induced parkinsonism.
Topics: Humans; Insecticides; Male; Middle Aged; Organophosphorus Compounds; Parkinson Disease, Secondary; P | 1978 |
Parkinson's disease improvement after the addition of levodopa-carbidopa to anticholinergic treatment. An open controlled study.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Drug Evaluation; Drug Therapy, Combination; Female; Hu | 1978 |
The coincidence of schizophrenia and Parkinsonism: some neurochemical implications.
Topics: Aged; Delusions; Dopamine; Female; Hallucinations; Humans; Middle Aged; Parkinson Disease, Postencep | 1976 |
[Combined treatment of Parkinsonism with levopa, midantan and anticholinergic drugs].
Topics: Acetylcholine; Adult; Aged; Amantadine; Antiparkinson Agents; Cholinesterases; Drug Therapy, Combina | 1976 |
[Appearance of parkinsonian syndrome after administration of delta sleep-inducing peptide into the rat substantia nigra].
Topics: Acute Disease; Animals; Caudate Nucleus; Delta Sleep-Inducing Peptide; Injections; Parkinson Disease | 1990 |
[Parkinson syndrome after administration of acetylcholine into the caudate nuclei].
Topics: Acetylcholine; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; Electrodes, Implanted; El | 1989 |
Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.
Topics: Adult; Aged; Antipsychotic Agents; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; | 1988 |
Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Clomipramine; | 1988 |
[Modelling of the parkinsonian syndrome by the administration of kainic acid into the caudate nucleus].
Topics: Animals; Caudate Nucleus; Disease Models, Animal; Drug Evaluation, Preclinical; Electrodes, Implante | 1987 |
The adverse effect of benzhexol on memory in Parkinson's disease.
Topics: Aged; Humans; Memory Disorders; Middle Aged; Parkinson Disease, Secondary; Trihexyphenidyl | 1987 |
[Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Diphenhydramine; Drug Therapy, Combination; g | 1974 |
[Study of extrapyramidal manifestations induced by neuroleptics].
Topics: Antiparkinson Agents; Chlorpromazine; Drug Synergism; Extrapyramidal Tracts; Fluphenazine; Haloperid | 1972 |
Fluphenazine-induced parkinsonism in the baboon: pharmacological and metabolic studies.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Carbon Isotopes; Chromatography, Thin Layer; Feces; Fe | 1972 |
Lack of indication for use of antiparkinson medication. A follow-up study.
Topics: Adolescent; Adult; Female; Follow-Up Studies; Humans; Intellectual Disability; Male; Mental Disorder | 1971 |
Pink spot--is it a drug artefact?
Topics: Amitriptyline; Amobarbital; Chlorpromazine; Chromatography; Haloperidol; Humans; Mental Disorders; P | 1970 |
Transitory procaine-induced Parkinsonism.
Topics: Chronic Disease; Dihydroxyphenylalanine; Female; Humans; Middle Aged; Parkinson Disease; Parkinson D | 1971 |
The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
Topics: Animals; Dextroamphetamine; Diphenhydramine; Imipramine; Iproniazid; Isocarboxazid; Mice; Monoamine | 1968 |
[Prolonged use of ponalid in extapyramidal drug-induced syndromes].
Topics: Humans; Movement Disorders; Parkinson Disease; Parkinson Disease, Secondary; Salivary Gland Diseases | 1966 |